QIAGEN Lake Constance is proud to announce a new test named PT Monitor® of our aLF Partner Abviris Deutschland GmbH.
PT Monitor® is a competitive immunoassay in rapid test format for the quantitative determination of DRH1 antibody equivalents in serum using the antibody clone DRH1.
The antibody concentration is associated with HPV16 induced precancerous lesions and tumors which are usually located in the oral and pharyngeal and anogenital area.
PT Monitor® is a single use test which is dedicated to professional users.
In combination with our aLF platform, this could be a gamechanger in the field of early HPV cancer diagnosis. Click here to learn more: https://abviris.com/